Dasiglucagon for the Treatment of Children with Congenital Hyperinsulinism

AddtoAny
Share:

WATCH THIS PAGE

Subscribe to be notified of changes or updates to this page.

14 + 4 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

This study is a 2 period, open label study that will evaluate the safety and efficacy of dasiglucagon in children between the ages of 3 months and 12 years. Dasiglucagon will be administered as a subcutaneous infusion. To be eligible, subjects are to have at least 3 or more hypoglycemic events a week, and are to have undergone a pancreatectomy for hyperinsulinism or are being treated with a non-surgical approach, because they were not eligible for pancreatic surgery.

Eligibility & Criteria

IRB #:
18-014906
Study Phase:
Phase III
Eligible Age Range:
3 Months - 12 Years
Gender:
Male
Study Categories: